<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999048</url>
  </required_header>
  <id_info>
    <org_study_id>2012CC47</org_study_id>
    <nct_id>NCT02999048</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Treatment of Hypertensive Intracerebral Hemorrhage With Panax Notoginseng Saponin</brief_title>
  <acronym>CSTHIHPNS</acronym>
  <official_title>Clinical Study on the Treatment of Hypertensive Cerebral Hemorrhage With Panax Notoginseng Saponins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First People's Hospital of Jingzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether panax notoginseng saponins are effective in
      the treatment of Hypertensive Intracerebral Hemorrhage Patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with HICH were randomly assigned to receive either PNS integrated with conventional
      therapy. Patients were treated with conventional therapy for 3 days, then plus PNS for 14
      days. Patients in the control group received conventional therapy for 17days. Hematoma volume
      measured by CT scanning, National Institutes of Health Stroke Scale (NIHSS) scores, Barthel
      index (BI), all the three were used to evaluate the therapeutic effect for both groups after
      two weeks of intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematoma volume</measure>
    <time_frame>within the 14 days after two weeks of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) scores</measure>
    <time_frame>within the 14 days after two weeks of intervention</time_frame>
    <description>were measured for stroke severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barthel index</measure>
    <time_frame>within the 14 days after two weeks of intervention</time_frame>
    <description>were measured for quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>such as rash, allergic shock</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hematoma Absorption and Neurological Function Recovery</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panax Notoginseng Saponins</intervention_name>
    <description>Panax Notoginseng Saponins integrated with conventional therapy</description>
    <arm_group_label>intervention group</arm_group_label>
    <other_name>XUESAITONG Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with a history of hypertension treated with medication and blood pressure management (
             a systolic blood-pressure target of 140 to 179 mmHg and a diastolic blood-pressure
             target of 70 to 100 mmHg) during the period of hospitalization,

          -  the site of hematoma located in one of the cerebral hemispheres,

          -  hematoma volume 10-30ml,

          -  no blood in the ventricles,

          -  within 24 hours of onset of first-time acute intracerebral hemorrhage,

          -  no loss of consciousness (drowsiness acceptable).

        Exclusion Criteria:

          -  cerebellar or brainstem hemorrhage,

          -  intracerebral hemorrhage caused by bleeding diathesis, aneurysms, vascular
             malformations, improperly using anticoagulant drugs, or suspicious amyloid angiopathy,

          -  subarachnoid hemorrhage; multifocal hemorrhage,

          -  mixed stroke or hemorrhagic infarct,

          -  coexisting systematic diseases such as heart or kidney failure, tumors,
             gastrointestinal hemorrhage and so on,

          -  pregnant or lactating women,

          -  a history of XUESAITONG injection anaphylaxis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Cheung RT. Update on medical and surgical management of intracerebral hemorrhage. Rev Recent Clin Trials. 2007 Sep;2(3):174-81. Review.</citation>
    <PMID>18474003</PMID>
  </results_reference>
  <results_reference>
    <citation>Nilsson OG, Lindgren A, Brandt L, SÃ¤veland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg. 2002 Sep;97(3):531-6.</citation>
    <PMID>12296635</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao X, Wang Y, Wang C, Li S, Wang Y, Yang Z. Quantitative evaluation for secondary injury to perihematoma of hypertensive cerebral hemorrhage by functional MR and correlation analysis with ischemic factors. Neurol Res. 2006 Jan;28(1):66-70.</citation>
    <PMID>16464365</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang DW, Han MK, Kim HJ, Yun SC, Jeon SB, Bae HJ, Kwon SU, Kim JS. New ischemic lesions coexisting with acute intracerebral hemorrhage. Neurology. 2012 Aug 28;79(9):848-55. doi: 10.1212/WNL.0b013e3182648a79. Epub 2012 Jul 25.</citation>
    <PMID>22843271</PMID>
  </results_reference>
  <results_reference>
    <citation>Li JY, Yuan LX, Zhang GM, Zhou L, Gao Y, Li QB, Chen C. Activating blood circulation to remove stasis treatment of hypertensive intracerebral hemorrhage: A multi-center prospective randomized open-label blinded-endpoint trial. Chin J Integr Med. 2016 May;22(5):328-34. doi: 10.1007/s11655-016-2467-7. Epub 2016 Apr 30.</citation>
    <PMID>27338955</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen X, Zhou M, Li Q, Yang J, Zhang Y, Zhang D, Kong S, Zhou D, He L. Sanchi for acute ischaemic stroke. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006305. doi: 10.1002/14651858.CD006305.pub2. Review.</citation>
    <PMID>18843711</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang X, Wu J, Zhang B. Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis. BMC Complement Altern Med. 2015 Feb 27;15:36. doi: 10.1186/s12906-015-0560-4. Review.</citation>
    <PMID>25888429</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim CH, Kim JS. Development of cerebral infarction shortly after intracerebral hemorrhage. Eur Neurol. 2007;57(3):145-9. Epub 2007 Jan 10.</citation>
    <PMID>17213720</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyquist P. Management of acute intracranial and intraventricular hemorrhage. Crit Care Med. 2010 Mar;38(3):946-53. doi: 10.1097/CCM.0b013e3181d16a04. Review.</citation>
    <PMID>20068459</PMID>
  </results_reference>
  <results_reference>
    <citation>Wasserman JK, Zhu X, Schlichter LC. Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. Brain Res. 2007 Nov 14;1180:140-54. Epub 2007 Sep 5.</citation>
    <PMID>17919462</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun K, Wang CS, Guo J, Liu YY, Wang F, Liu LY, He JG, Fan JY, Han JY. Effect of Panax notoginseng saponins on lipopolysaccharide-induced adhesion of leukocytes in rat mesenteric venules. Clin Hemorheol Microcirc. 2006;34(1-2):103-8.</citation>
    <PMID>16543624</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang YX, Yan A, Ma ZH, Wang Z, Zhang B, Ping JL, Zhu JS, Zhou Y, Dai L. Nuclear factor-ÎºB and apoptosis in patients with intracerebral hemorrhage. J Clin Neurosci. 2011 Oct;18(10):1392-5. doi: 10.1016/j.jocn.2010.11.039. Epub 2011 Jul 22.</citation>
    <PMID>21782444</PMID>
  </results_reference>
  <results_reference>
    <citation>Li H, Deng CQ, Chen BY, Zhang SP, Liang Y, Luo XG. Total saponins of Panax notoginseng modulate the expression of caspases and attenuate apoptosis in rats following focal cerebral ischemia-reperfusion. J Ethnopharmacol. 2009 Jan 30;121(3):412-8. doi: 10.1016/j.jep.2008.10.042. Epub 2008 Nov 18.</citation>
    <PMID>19059471</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First People's Hospital of Jingzhou</investigator_affiliation>
    <investigator_full_name>Zhijian Luo</investigator_full_name>
    <investigator_title>deputy chief physician, neurology physician</investigator_title>
  </responsible_party>
  <keyword>panax notoginseng saponins</keyword>
  <keyword>hypertensive intracerebral hemorrhage</keyword>
  <keyword>hematoma</keyword>
  <keyword>neurological function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

